Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.

J Cancer Res Clin Oncol · 2024 · PMC11062962 · PMID 38693452

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

A study conducted by the US Lymphoma CAR-T Consortium showed that patients who received bridging therapy showed a trend toward inferior PFS compared to non-bridged patients (p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.